Salud financiera de hoja de balance de Talphera

Salud financiera controles de criterios 6/6

Talphera tiene un patrimonio de los accionistas total de $14.1M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $20.4M y $6.3M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$9.38m
Patrimonio	US$14.11m
Total pasivo	US$6.29m
Activos totales	US$20.40m

Actualizaciones recientes sobre salud financiera

Recent updates

AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well

Aug 18

AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm

Jul 27

FDA agrees with AcelRx to update promotional materials for Dsuvia

Jun 17

Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now

Jun 11

AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles

May 31

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($11.6M) de TLPH superan a sus pasivos a corto plazo ($4.5M).

Pasivo a largo plazo: Los activos a corto plazo de TLPH ($11.6M) superan a sus pasivos a largo plazo ($1.8M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: TLPH está libre de deudas.

Reducción de la deuda: TLPH no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 2484.6%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: TLPH tiene suficiente cash runway para 6 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: TLPH dispone de suficiente cash runway para 1 años si el flujo de caja libre sigue creciendo a tasas históricas de 7.3% cada año.

Salud financiera de hoja de balance de Talphera

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

AcelRx Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Acelrx Pharmaceuticals Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule

AcelRx Pharmaceuticals Announces Reverse Stock Split to Regain Compliance

Nasdaq Grants Additional time to AcelRx Pharmaceuticals to Regain Compliance

AcelRx Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Recent updates

Talphera, Inc. to Report Q1, 2024 Results on May 14, 2024

Talphera, Inc., Annual General Meeting, Jun 24, 2024

Talphera, Inc. to Report Q4, 2023 Results on Mar 06, 2024

New major risk - Share price stability

Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director

Talphera, Inc.(NasdaqGM:TLPH) dropped from NASDAQ Composite Index

Talphera Expects to Initiate the Registrational Study of Niyad

New major risk - Financial position

Consensus EPS estimates upgraded to US$1.16 loss, revenue downgraded

AcelRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

AcelRx Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

AcelRx Pharmaceuticals, Inc. Receives IDE Approval for Niyad and Advances to A Single Registration Study

AcelRx Pharmaceuticals, Inc., Annual General Meeting, Oct 10, 2023

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AcelRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Shareholder dilution

Acelrx Pharmaceuticals Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule

First quarter 2023 earnings released: EPS: US$0.006 (vs US$1.19 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.00

AcelRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022

AcelRx Pharmaceuticals Announces Reverse Stock Split to Regain Compliance

Consensus forecasts updated

Consensus forecasts updated

AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

AcelRx Pharmaceuticals, Inc. announced that it has received $0.3 million in funding from Lincoln Park Capital, LLC

Nasdaq Grants Additional time to AcelRx Pharmaceuticals to Regain Compliance

AcelRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

AcelRx Pharmaceuticals: Finally, Plan B

AcelRx Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates fall by 16%

AcelRx Pharmaceuticals, Inc. Provides Update on Reduced FDA REMS Requirements Related to DSUVIA

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Acelrx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (Sst) Compared to Standard Intravenous Opioids During Plastic Surgery Procedures Performed Under General Anesthesia

AcelRx Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$4.00

AcelRx Pharmaceuticals, Inc. Announces Summary of Results from Podium Presentation on DSUVIA, at the Aesthetic Meeting 2022

AcelRx Pharmaceuticals, Inc. Announces Publication of A Study Evaluating the Use of A Sufentanil Sublingual Tablet 30 Mcg for Management of Pain of Radiofrequency Microneedling of the Face or Abdomen

AcelRx Pharmaceuticals, Inc. Announces the Publication of Comparative Data Between Two Different Dialysis Circuit Anticoagulants in Pediatric Patients Undergoing Continuous Renal Replacement Therapy

Consensus forecasts updated

AcelRx Pharmaceuticals: Making Sense Of The Q4 Numbers

Full year 2021 earnings: EPS and revenues miss analyst expectations

AcelRx Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

AcelRx Pharmaceuticals, Inc. Announces Resignation of Mark G. Edwards as Board of Director

AcelRx Pharmaceuticals, Inc. Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet During Awake Plastic Surgery Procedures

AcelRx Pharmaceuticals: The Fog Is Getting Thicker

AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX) completed the acquisition of Lowell Therapeutics, Inc.

AcelRx: Battered And Bruised But Ready For Recovery In 2022

AcelRx Pharmaceuticals, Inc. Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery

Consensus revenue estimates fall to US$4.66m

No longer forecast to breakeven

Price target decreased to US$4.25

Third quarter 2021 earnings released: US$0.07 loss per share (vs US$0.10 loss in 3Q 2020)

AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?

Second quarter 2021 earnings released: US$0.083 loss per share (vs US$0.082 loss in 2Q 2020)

AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm

AcelRx Pharmaceuticals, Inc.(NasdaqGM:ACRX) dropped from Russell 3000E Value Index

Rosen Law Firm Reminds Purchasers of the Securities of Acelrx Pharmaceuticals, Inc. Between March 17, 2020 and February 12, 2021

FDA agrees with AcelRx to update promotional materials for Dsuvia

Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now

Pomerantz Law Firm Announces the Filing of A Class Action Against AcelRX Pharmaceuticals, Inc. and Certain Officers

AcelRx Pharmaceuticals, Inc. Announces Important Findings from A Podium Presentation on DSUVIA

AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles

Consensus revenue estimates fall to US$8.76m

Price target increased to US$6.67